ACRO Biomedical Co., Ltd. Statistics
ACRO Biomedical Co., Ltd. (6748) Stock Statistics & Valuation Metrics
Total Valuation
ACRO Biomedical Co., Ltd. has a market cap or net worth of TWD 11.47B. The enterprise value is ―.
- Market Cap
- TWD 11.47B
- Enterprise Value
- ―
Share Statistics
ACRO Biomedical Co., Ltd. has 71,683,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 71,683,200
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
ACRO Biomedical Co., Ltd.’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -8.27%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -8.27%
- Return on Capital Employed (ROCE)
- -0.08
- Revenue Per Employee
- 910.83K
- Profits Per Employee
- -1.97M
- Employee Count
- 42
- Asset Turnover
- 0.03
- Inventory Turnover
- 2.05
Valuation Ratios
The current PE Ratio of ACRO Biomedical Co., Ltd. is -97.19. ACRO Biomedical Co., Ltd.’s PEG ratio is 7.83.
- PE Ratio
- -97.19
- PS Ratio
- 156.71
- PB Ratio
- 11.66
- Price to FCF
- -101.38
- Price to Operating Cash Flow
- -114.55
- PEG Ratio
- 7.83
Income Statement
In the last 12 months, ACRO Biomedical Co., Ltd. had revenue of 38.26M and earned -82.66M in profits. Earnings per share was -1.35.
- Revenue
- 38.26M
- Gross Profit
- 12.17M
- Operating Income
- -92.22M
- Pretax Income
- -82.66M
- Net Income
- -82.66M
- EBITDA
- -75.68M
- Earnings Per Share (EPS)
- -1.35
Cash Flow
In the last 12 months, operating cash flow was -108.49M and capital expenditures -13.83M, giving a free cash flow of -122.32M billion.
- Operating Cash Flow
- -108.49M
- Free Cash Flow
- -122.32M
- Free Cash Flow per Share
- -1.70
Dividends & Yields
ACRO Biomedical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.99%
- Earnings Yield
- -0.95%
Stock Price Statistics
- Beta
- -0.62
- 52-Week Price Change
- 151.09%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 33.32
- Average Volume (3m)
- 537.69K
Financial Position
ACRO Biomedical Co., Ltd. as a current ratio of 51.12, with Debt / Equity ratio of 0.96%
- Current Ratio
- 51.12
- Quick Ratio
- 50.47
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 10.04
- Interest Coverage Ratio
- -411.68
Taxes
In the past 12 months, ACRO Biomedical Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
ACRO Biomedical Co., Ltd. EV to EBITDA ratio is -102.20, with an EV/FCF ratio of -97.98.
- EV to Sales
- 151.45
- EV to EBITDA
- -102.20
- EV to Free Cash Flow
- -97.98
- EV to Operating Cash Flow
- -110.48
Balance Sheet
ACRO Biomedical Co., Ltd. has TWD 916.68M in cash and marketable securities with TWD 33.63M in debt, giving a net cash position of TWD 883.05M billion.
- Cash & Marketable Securities
- TWD 916.68M
- Total Debt
- TWD 33.63M
- Net Cash
- TWD 883.05M
- Net Cash Per Share
- TWD 12.32
- Tangible Book Value Per Share
- TWD 14.75
Margins
Gross margin is 64.16%, with operating margin of -178.30%, and net profit margin of -149.34%.
- Gross Margin
- 64.16%
- Operating Margin
- -178.30%
- Pretax Margin
- -149.34%
- Net Profit Margin
- -149.34%
- EBITDA Margin
- -148.19%
- EBIT Margin
- -178.30%
Analyst Forecast
The average price target for ACRO Biomedical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 44.54%
- EPS Growth Forecast
- 14.25%
